Alterity Therapeutics Management
Management criteria checks 3/4
Alterity Therapeutics' CEO is David Stamler, appointed in Jan 2021, has a tenure of 3.92 years. total yearly compensation is A$1.42M, comprised of 50.4% salary and 49.6% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth A$58.84K. The average tenure of the management team and the board of directors is 12.9 years and 18.6 years respectively.
Key information
David Stamler
Chief executive officer
AU$1.4m
Total compensation
| CEO salary percentage | 50.4% |
| CEO tenure | 3.9yrs |
| CEO ownership | 0.2% |
| Management average tenure | 12.9yrs |
| Board average tenure | 18.6yrs |
Recent management updates
Recent updates
Shareholders May Be More Conservative With Alterity Therapeutics Limited's (ASX:ATH) CEO Compensation For Now
Nov 23
We're Keeping An Eye On Alterity Therapeutics' (ASX:ATH) Cash Burn Rate
Jun 28Is Alterity Therapeutics (ASX:ATH) In A Good Position To Invest In Growth?
Mar 07We're Hopeful That Alterity Therapeutics (ASX:ATH) Will Use Its Cash Wisely
May 16Here's Why We're Watching Alterity Therapeutics' (ASX:ATH) Cash Burn Situation
Jan 31How Much Is Alterity Therapeutics Limited (ASX:ATH) CEO Getting Paid?
Dec 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$1m | AU$717k | -AU$19m |
| Mar 31 2024 | n/a | n/a | -AU$16m |
| Dec 31 2023 | n/a | n/a | -AU$12m |
| Sep 30 2023 | n/a | n/a | -AU$13m |
| Jun 30 2023 | AU$2m | AU$731k | -AU$14m |
| Mar 31 2023 | n/a | n/a | -AU$14m |
| Dec 31 2022 | n/a | n/a | -AU$14m |
| Sep 30 2022 | n/a | n/a | -AU$14m |
| Jun 30 2022 | AU$2m | AU$658k | -AU$13m |
| Mar 31 2022 | n/a | n/a | -AU$13m |
| Dec 31 2021 | n/a | n/a | -AU$13m |
| Sep 30 2021 | n/a | n/a | -AU$14m |
| Jun 30 2021 | AU$979k | AU$606k | -AU$15m |
| Mar 31 2021 | n/a | n/a | -AU$16m |
| Dec 31 2020 | n/a | n/a | -AU$16m |
| Sep 30 2020 | n/a | n/a | -AU$15m |
| Jun 30 2020 | AU$625k | AU$625k | -AU$13m |
| Mar 31 2020 | n/a | n/a | -AU$13m |
| Dec 31 2019 | n/a | n/a | -AU$13m |
| Sep 30 2019 | n/a | n/a | -AU$12m |
| Jun 30 2019 | AU$548k | AU$548k | -AU$12m |
| Mar 31 2019 | n/a | n/a | -AU$11m |
| Dec 31 2018 | n/a | n/a | -AU$10m |
| Sep 30 2018 | n/a | n/a | -AU$9m |
| Jun 30 2018 | AU$630k | AU$504k | -AU$8m |
Compensation vs Market: David's total compensation ($USD889.40K) is above average for companies of similar size in the Australian market ($USD291.28K).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
CEO
David Stamler (63 yo)
3.9yrs
Tenure
AU$1,422,068
Compensation
Dr. David A. Stamler, M.D., serves as Chief Executive Officer at Alterity Therapeutics Limited since January 07, 2021. Dr. Stamler had been the Chief Medical Officer and Senior Vice President of Clinical D...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Non-Executive Chairman | 27.1yrs | AU$280.00k | 0.28% A$ 81.4k | |
| Chief Executive Officer | 3.9yrs | AU$1.42m | 0.20% A$ 58.8k | |
| CFO & Company Secretary | less than a year | no data | no data | |
| Chief Scientific Advisor and Member of Research & Development Advisory Board | 12.9yrs | no data | no data | |
| Chief Medical Advisor | 17.8yrs | no data | no data | |
| Head of Research | 17.7yrs | no data | no data |
12.9yrs
Average Tenure
66yo
Average Age
Experienced Management: ATH's management team is seasoned and experienced (12.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Non-Executive Chairman | 27.1yrs | AU$280.00k | 0.28% A$ 81.4k | |
| Chief Scientific Advisor and Member of Research & Development Advisory Board | 17.8yrs | no data | no data | |
| Non-Executive Independent Director | 25yrs | AU$70.00k | 0.14% A$ 41.1k | |
| Member of Research & Development Advisory Board | 17.8yrs | AU$241.36k | no data | |
| Non-Executive Independent Director | 19.4yrs | AU$70.00k | 0.14% A$ 39.5k | |
| Non-Executive Director | 13.3yrs | AU$70.00k | no data | |
| Chairman of Research & Development Advisory Board | no data | AU$78.76k | no data |
18.6yrs
Average Tenure
69yo
Average Age
Experienced Board: ATH's board of directors are seasoned and experienced ( 18.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:39 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Alterity Therapeutics Limited is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| George Zavoico | B. Riley Securities, Inc. |
| Vernon Bernardino | FBR Capital Markets & Co. |
| George Zavoico | H.C. Wainwright & Co. |